Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2005;331:779 (1 October), doi:10.1136/bmj.331.7519.779-a
| The first 150 words of the full text of this article appear below. |
EDITORBreast cancer is a rapidly emerging disease in Africa.1 It has similar implications for African women as HIV, but it receives little attention in terms of publicity, funding (both overseas and internally), and local research. Affected women are young and poor and present with late stage disease. Five year survival is 5-15% compared with over 60% in developed countries.2 3 The disease is controlled by mutilating surgery. Without prosthetic support, the patient rapidly loses self esteem and may die young.
We encountered many challenges with research governance in studying the pattern of occurrence and molecular genetic variations of breast cancer in Nigeria and the UK.4 Ethics approval in Nigeria is not well structured. Existing consent forms are generic and do not cover special collaborations such as genetic studies. Tracing patients to request consent for the use of archive material is difficult. Post and telecommunications do not always work. Record
Isaac D Gukas, lecturer
i.gukas@uea.ac.uk
School of Medicine, Health Policy and Practice, University of East Anglia, Norwich NR4 7TJ
Barbara A Jennings, senior lecturer, Samuel J Leinster, professor of medical education, Ian Harvey, professor of epidemiology
School of Medicine, Health Policy and Practice, University of East Anglia, Norwich NR4 7TJ